comparemela.com

Latest Breaking News On - Noxxon pharmanv stock exchange - Page 1 : comparemela.com

NOXXON Pharma N : enrolls last brain cancer patient in dose escalation portion of GLORIA study and confirms phase 1/2 read-out in Q1 2022

NOXXON ENROLLS LAST BRAIN CANCER PATIENT IN DOSE ESCALATION PORTION OF GLORIA STUDY AND CONFIRMS PHASE 1/2 READ-OUT IN Q1 2022 . | September 22, 2021

France generalUlf jungneliusPharmanv euronextNewcap arthur rouillGuillaume van renterghemEuronext growth parisJarl ulf jungneliusSenior medical advisorExecutive officerMedia relationsCap arthur rouillநிர்வாகி அதிகாரிமீடியா உறவுகள்Noxxon pharmanv stock exchangePress release1 alnox nl0012044762

NOXXON Pharma N : announces manufacturing of NOX-A12 drug substance for future clinical trials and issuance of convertible bonds under financing agreement with Atlas

NOXXON ANNOUNCES MANUFACTURING OF NOX-A12 DRUG SUBSTANCE FOR FUTURE CLINICAL TRIALS AND ISSUANCE OF CONVERTIBLE BONDS UNDER FINANCING. | June 1, 2021

Newcap arthur rouillGuillaume van renterghemMerck sharp dohme corpExecutive officerMedia relationsCap arthur rouillMerck sharpDohme corpNoxxon pharmanv stock exchangePress releaseOnds alnox nl0012044762நிர்வாகி அதிகாரிமீடியா உறவுகள்மெர்க் கூர்மையான

NOXXON Pharma N : announces convocation of its hybrid 2021 annual general meeting of shareholders

NOXXON ANNOUNCES CONVOCATION OF ITS HYBRID 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS Strengthening of the Supervisory Board through the binding nominations of . | May 25, 2021

Rheinland pfalzUnited statesUnited kingdomFrance generalTrinity universitySan antonioNoord hollandGuillaume van renterghemLaboratoires fournierHolland bioSusan colesPharmanv euronextMartine van vugtNewcap arthur rouillMaurizio petitbonUniversity of wageningen

NOXXON Pharma N : Announces Capital Increase of €6 4 Million by Private Placement to Further Develop Its Business

Regulatory News: NOXXON Pharma N.V. a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment , announced today the successful completion of its. | February 8, 2021

Aram mangasarianMerck sharp dohme corpRegulatory newsEuronext growth parisSupervisory boardMarsac advisorsLead managerHalf year financial reportAnnual reportMerck sharpNoxxon pharmanv stock exchangePress releaseOf alnox nl0012044762ஒழுங்குமுறை செய்திமேற்பார்வை பலகைவழி நடத்து மேலாளர்

vimarsana © 2020. All Rights Reserved.